Top

06-05-2024 | Chronic Kidney Disease | Original Contribution

Lactobacillus acidophilus KBL409 protects against kidney injury via improving mitochondrial function with chronic kidney disease

Authors: Jimin Park, Ki Heon Nam, Bo Young Nam, Gyuri Kim, Hyoungnae Kim, Ki Uk Lee, Seok Cheon Song, Tae-Wook Nam, Woon-Ki Kim, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, GwangPyo Ko, Seung Hyeok Han

Published in: European Journal of Nutrition

Abstract

Purpose

Recent advances have led to greater recognition of the role of mitochondrial dysfunction in the pathogenesis of chronic kidney disease (CKD). There has been evidence that CKD is also associated with dysbiosis. Here, we aimed to evaluate whether probiotic supplements can have protective effects against kidney injury via improving mitochondrial function.

Methods

An animal model of CKD was induced by feeding C57BL/6 mice a diet containing 0.2% adenine. KBL409, a strain of Lactobacillus acidophilus, was administered via oral gavage at a dose of 1 × 10⁹ CFU daily. To clarify the underlying mechanisms by which probiotics exert protective effects on mitochondria in CKD, primary mouse tubular epithelial cells stimulated with TGF-β and p-cresyl sulfate were administered with butyrate.

Results

In CKD mice, PGC-1α and AMPK, key mitochondrial energy metabolism regulators, were down-regulated. In addition, mitochondrial dynamics shifted toward fission, the number of fragmented cristae increased, and mitochondrial mass decreased. These alterations were restored by KBL409 administration. KBL409 supplementation also improved defects in fatty acid oxidation and glycolysis and restored the suppressed enzyme levels involved in TCA cycle. Accordingly, there was a concomitant improvement in mitochondrial respiration and ATP production assessed by mitochondrial function assay. These favorable effects of KBL409 on mitochondria ultimately decreased kidney fibrosis in CKD mice. In vitro analyses with butyrate recapitulated the findings of animal study.

Conclusions

This study demonstrates that administration of the probiotic Lactobacillus acidophilus KBL409 protects against kidney injury via improving mitochondrial function.

Available only for authorised users

Wang Z, Ying Z, Bosy-Westphal A, Zhang J, Schautz B, Later W, Heymsfield SB, Muller MJ (2010) Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditure. Am J Clin Nutr 92(6):1369–1377. https://doi.org/10.3945/ajcn.2010.29885CrossRefPubMedPubMedCentral

Che R, Yuan Y, Huang S, Zhang A (2014) Mitochondrial dysfunction in the pathophysiology of renal diseases. Am J Physiol Renal Physiol 306(4):F367-378. https://doi.org/10.1152/ajprenal.00571.2013CrossRefPubMed

Galvan DL, Green NH, Danesh FR (2017) The hallmarks of mitochondrial dysfunction in chronic kidney disease. Kidney Int 92(5):1051–1057. https://doi.org/10.1016/j.kint.2017.05.034CrossRefPubMedPubMedCentral

Coughlan MT, Nguyen TV, Penfold SA, Higgins GC, Thallas-Bonke V, Tan SM, Van Bergen NJ, Sourris KC, Harcourt BE, Thorburn DR, Trounce IA, Cooper ME, Forbes JM (2016) Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. Clin Sci (Lond) 130(9):711–720. https://doi.org/10.1042/cs20150838CrossRefPubMed

Zhan M, Brooks C, Liu FY, Sun L, Dong Z (2013) Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int 83(4):568–581. https://doi.org/10.1038/ki.2012.441CrossRefPubMedPubMedCentral

Tang C, Cai J, Dong Z (2016) Mitochondrial dysfunction in obesity-related kidney disease: a novel therapeutic target. Kidney Int 90(5):930–933. https://doi.org/10.1016/j.kint.2016.07.045CrossRefPubMed

Szeto HH (2017) Pharmacologic approaches to improve mitochondrial function in AKI and CKD. J Am Soc Nephrol 28(10):2856–2865. https://doi.org/10.1681/ASN.2017030247CrossRefPubMedPubMedCentral

Forbes JM, Thorburn DR (2018) Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol 14(5):291–312. https://doi.org/10.1038/nrneph.2018.9CrossRefPubMed

Bhatia D, Capili A, Choi ME (2020) Mitochondrial dysfunction in kidney injury, inflammation, and disease: potential therapeutic approaches. Kidney Res Clin Pract 39(3):244–258. https://doi.org/10.23876/j.krcp.20.082

10.

Dare AJ, Bolton EA, Pettigrew GJ, Bradley JA, Saeb-Parsy K, Murphy MP (2015) Protection against renal ischemia-reperfusion injury in vivo by the mitochondria targeted antioxidant MitoQ. Redox Biol 5:163–168. https://doi.org/10.1016/j.redox.2015.04.008CrossRefPubMedPubMedCentral

11.

Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, Su D, Hwang MT, Fan X, Davis L, Striker G, Zheng F, Breyer M, Guan Y (2006) PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69(9):1511–1517. https://doi.org/10.1038/sj.ki.5000209CrossRefPubMed

12.

Yang HC, Deleuze S, Zuo Y, Potthoff SA, Ma LJ, Fogo AB (2009) The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol 20(11):2380–2388. https://doi.org/10.1681/ASN.2008111138CrossRefPubMedPubMedCentral

13.

Ayanga BA, Badal SS, Wang Y, Galvan DL, Chang BH, Schumacker PT, Danesh FR (2016) Dynamin-related protein 1 deficiency improves mitochondrial fitness and protects against progression of diabetic nephropathy. J Am Soc Nephrol 27(9):2733–2747. https://doi.org/10.1681/ASN.2015101096CrossRefPubMedPubMedCentral

14.

Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D (2015) Role of the normal gut microbiota. World J Gastroenterol 21(29):8787–8803. https://doi.org/10.3748/wjg.v21.i29.8787CrossRefPubMedPubMedCentral

15.

Koppe L, Mafra D, Fouque D (2015) Probiotics and chronic kidney disease. Kidney Int 88(5):958–966. https://doi.org/10.1038/ki.2015.255CrossRefPubMed

16.

Lau WL, Savoj J, Nakata MB, Vaziri ND (2018) Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins. Clin Sci (Lond) 132(5):509–522. https://doi.org/10.1042/CS20171107CrossRefPubMed

17.

Andrade-Oliveira V, Amano MT, Correa-Costa M, Castoldi A, Felizardo RJ, de Almeida DC, Bassi EJ, Moraes-Vieira PM, Hiyane MI, Rodas AC, Peron JP, Aguiar CF, Reis MA, Ribeiro WR, Valduga CJ, Curi R, Vinolo MA, Ferreira CM, Câmara NO (2015) Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 26(8):1877–1888. https://doi.org/10.1681/asn.2014030288CrossRefPubMedPubMedCentral

18.

Yang J, Lim SY, Ko YS, Lee HY, Oh SW, Kim MG, Cho WY, Jo SK (2019) Intestinal barrier disruption and dysregulated mucosal immunity contribute to kidney fibrosis in chronic kidney disease. Nephrol Dial Transplant 34(3):419–428. https://doi.org/10.1093/ndt/gfy172CrossRefPubMed

19.

Iwashita Y, Ohya M, Yashiro M, Sonou T, Kawakami K, Nakashima Y, Yano T, Iwashita Y, Mima T, Negi S, Kubo K, Tomoda K, Odamaki T, Shigematsu T (2018) Dietary changes involving bifidobacterium longum and other nutrients delays chronic kidney disease progression. Am J Nephrol 47(5):325–332. https://doi.org/10.1159/000488947CrossRefPubMed

20.

Yoshifuji A, Wakino S, Irie J, Tajima T, Hasegawa K, Kanda T, Tokuyama H, Hayashi K, Itoh H (2016) Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol Dial Transplant 31(3):401–412. https://doi.org/10.1093/ndt/gfv353CrossRefPubMed

21.

Wei M, Wang Z, Liu H, Jiang H, Wang M, Liang S, Shi K, Feng J (2014) Probiotic Bifidobacterium animalis subsp. lactis Bi-07 alleviates bacterial translocation and ameliorates microinflammation in experimental uraemia. Nephrology (Carlton) 19(8):500–506. https://doi.org/10.1111/nep.12272

22.

Xia B, Yu J, He T, Liu X, Su J, Wang M, Wang J, Zhu Y (2020) Lactobacillus johnsonii L531 ameliorates enteritis via elimination of damaged mitochondria and suppression of SQSTM1-dependent mitophagy in a Salmonella infantis model of piglet diarrhea. Faseb j 34(2):2821–2839. https://doi.org/10.1096/fj.201901445RRRCrossRefPubMed

23.

Tunapong W, Apaijai N, Yasom S, Tanajak P, Wanchai K, Chunchai T, Kerdphoo S, Eaimworawuthikul S, Thiennimitr P, Pongchaidecha A, Lungkaphin A, Pratchayasakul W, Chattipakorn SC, Chattipakorn N (2018) Chronic treatment with prebiotics, probiotics and synbiotics attenuated cardiac dysfunction by improving cardiac mitochondrial dysfunction in male obese insulin-resistant rats. Eur J Nutr 57(6):2091–2104. https://doi.org/10.1007/s00394-017-1482-3CrossRefPubMed

24.

d’Ettorre G, Rossi G, Scagnolari C, Andreotti M, Giustini N, Serafino S, Schietroma I, Scheri GC, Fard SN, Trinchieri V, Mastromarino P, Selvaggi C, Scarpona S, Fanello G, Fiocca F, Ceccarelli G, Antonelli G, Brenchley JM, Vullo V (2017) Probiotic supplementation promotes a reduction in T-cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ART-treated HIV-1-positive patients. Immun Inflamm Dis 5(3):244–260. https://doi.org/10.1002/iid3.160CrossRefPubMedPubMedCentral

25.

Ren T, Zhu L, Shen Y, Mou Q, Lin T, Feng H (2019) Protection of hepatocyte mitochondrial function by blueberry juice and probiotics via SIRT1 regulation in non-alcoholic fatty liver disease. Food Funct 10(3):1540–1551. https://doi.org/10.1039/c8fo02298dCrossRefPubMed

26.

Kim WK, Han DH, Jang YJ, Park S, Jang SJ, Lee G, Han HS, Ko G (2021) Alleviation of DSS-induced colitis via Lactobacillus acidophilus treatment in mice. Food Funct 12(1):340–350. https://doi.org/10.1039/d0fo01724hCrossRefPubMed

27.

Kim H, Nam BY, Park J, Song S, Kim WK, Lee K, Nam TW, Park JT, Yoo TH, Kang SW, Ko G, Han SH (2022) Lactobacillus acidophilus KBL409 reduces kidney fibrosis via immune modulatory effects in mice with chronic kidney disease. Mol Nutr Food Res:e2101105. https://doi.org/10.1002/mnfr.202101105

28.

Murase M, Kimura Y, Nagata Y (1995) Determination of portal short-chain fatty acids in rats fed various dietary fibers by capillary gas chromatography. J Chromatogr B Biomed Appl 664(2):415–420. https://doi.org/10.1016/0378-4347(94)00491-mCrossRefPubMed

29.

Li YJ, Chen X, Kwan TK, Loh YW, Singer J, Liu Y, Ma J, Tan J, Macia L, Mackay CR, Chadban SJ, Wu H (2020) Dietary fiber protects against diabetic nephropathy through short-chain fatty acid-mediated activation of G protein-coupled receptors GPR43 and GPR109A. J Am Soc Nephrol 31(6):1267–1281. https://doi.org/10.1681/ASN.2019101029CrossRefPubMedPubMedCentral

30.

Huang W, Guo HL, Deng X, Zhu TT, Xiong JF, Xu YH, Xu Y (2017) Short-chain fatty acids inhibit oxidative stress and inflammation in mesangial cells induced by high glucose and lipopolysaccharide. Exp Clin Endocrinol Diabetes 125(2):98–105. https://doi.org/10.1055/s-0042-121493CrossRefPubMed

31.

Matsumoto N, Riley S, Fraser D, Al-Assaf S, Ishimura E, Wolever T, Phillips GO, Phillips AO (2006) Butyrate modulates TGF-beta1 generation and function: potential renal benefit for Acacia(sen) SUPERGUM (gum arabic)? Kidney Int 69(2):257–265. https://doi.org/10.1038/sj.ki.5000028CrossRefPubMed

32.

Mollica MP, Mattace Raso G, Cavaliere G, Trinchese G, De Filippo C, Aceto S, Prisco M, Pirozzi C, Di Guida F, Lama A, Crispino M, Tronino D, Di Vaio P, Berni Canani R, Calignano A, Meli R (2017) Butyrate regulates liver mitochondrial function, efficiency, and dynamics in insulin-resistant obese mice. Diabetes 66(5):1405–1418. https://doi.org/10.2337/db16-0924CrossRefPubMed

33.

Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J (2009) Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58(7):1509–1517. https://doi.org/10.2337/db08-1637CrossRefPubMedPubMedCentral

34.

Hu J, Kyrou I, Tan BK, Dimitriadis GK, Ramanjaneya M, Tripathi G, Patel V, James S, Kawan M, Chen J, Randeva HS (2016) Short-chain fatty acid acetate stimulates adipogenesis and mitochondrial biogenesis via GPR43 in brown adipocytes. Endocrinology 157(5):1881–1894. https://doi.org/10.1210/en.2015-1944CrossRefPubMed

35.

Hu S, Kuwabara R, de Haan BJ, Smink AM, de Vos P (2020) Acetate and butyrate improve β-cell metabolism and mitochondrial respiration under oxidative stress. Int J Mol Sci. https://doi.org/10.3390/ijms21041542

36.

Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL (2013) Chronic kidney disease alters intestinal microbial flora. Kidney Int 83(2):308–315. https://doi.org/10.1038/ki.2012.345CrossRefPubMed

37.

Diwan V, Brown L, Gobe GC (2018) Adenine-induced chronic kidney disease in rats. Nephrology (Carlton) 23(1):5–11. https://doi.org/10.1111/nep.13180CrossRefPubMed

38.

Charan J, Kantharia ND (2013) How to calculate sample size in animal studies? J Pharmacol Pharmacother 4(4):303–306. https://doi.org/10.4103/0976-500X.119726CrossRefPubMedPubMedCentral

39.

Oh HJ, Nam BY, Wu M, Kim S, Park J, Kang S, Park JT, Yoo TH, Kang SW, Han SH (2018) Klotho plays a protective role against glomerular hypertrophy in a cell cycle-dependent manner in diabetic nephropathy. Am J Physiol Renal Physiol 315(4):F791–F805. https://doi.org/10.1152/ajprenal.00462.2017CrossRefPubMed

40.

Nangaku M, Pippin J, Couser WG (1999) Complement membrane attack complex (C5b–9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 10(11):2323–2331. https://doi.org/10.1681/ASN.V10112323CrossRefPubMed

41.

Vaziri ND, Yuan J, Rahimi A, Ni Z, Said H, Subramanian VS (2012) Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transpl 27(7):2686–2693. https://doi.org/10.1093/ndt/gfr624CrossRef

42.

Andersen K, Kesper MS, Marschner JA, Konrad L, Ryu M, Kumar Vr S, Kulkarni OP, Mulay SR, Romoli S, Demleitner J, Schiller P, Dietrich A, Muller S, Gross O, Ruscheweyh HJ, Huson DH, Stecher B, Anders HJ (2017) Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. J Am Soc Nephrol 28(1):76–83. https://doi.org/10.1681/ASN.2015111285CrossRefPubMed

43.

Miranda Alatriste PV, Urbina Arronte R, Gomez Espinosa CO, Espinosa Cuevas Mde L (2014) Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp 29(3):582–590. https://doi.org/10.3305/nh.2014.29.3.7179CrossRefPubMed

44.

Natarajan R, Pechenyak B, Vyas U, Ranganathan P, Weinberg A, Liang P, Mallappallil MC, Norin AJ, Friedman EA, Saggi SJ (2014) Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res Int 2014:568571. https://doi.org/10.1155/2014/568571CrossRefPubMedPubMedCentral

45.

Rossi M, Johnson DW, Morrison M, Pascoe EM, Coombes JS, Forbes JM, Szeto CC, McWhinney BC, Ungerer JP, Campbell KL (2016) Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clin J Am Soc Nephrol 11(2):223–231. https://doi.org/10.2215/CJN.05240515CrossRefPubMedPubMedCentral

46.

Borges NA, Carmo FL, Stockler-Pinto MB, de Brito JS, Dolenga CJ, Ferreira DC, Nakao LS, Rosado A, Fouque D, Mafra D (2018) Probiotic supplementation in chronic kidney disease: a double-blind, randomized, placebo-controlled. Trial J Ren Nutr 28(1):28–36. https://doi.org/10.1053/j.jrn.2017.06.010CrossRefPubMed

47.

Eidi F, Poor-Reza Gholi F, Ostadrahimi A, Dalili N, Samadian F, Barzegari A (2018) Effect of Lactobacillus Rhamnosus on serum uremic toxins (phenol and P-Cresol) in hemodialysis patients: a double blind randomized clinical trial. Clin Nutr ESPEN 28:158–164. https://doi.org/10.1016/j.clnesp.2018.08.010CrossRefPubMed

48.

Borges NA, Stenvinkel P, Bergman P, Qureshi AR, Lindholm B, Moraes C, Stockler-Pinto MB, Mafra D (2019) Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in hemodialysis patients: a pilot study. Probiotics Antimicrob Proteins 11(2):648–654. https://doi.org/10.1007/s12602-018-9411-1CrossRefPubMed

49.

Lopes R, Theodoro JMV, da Silva BP, Queiroz VAV, de Castro Moreira ME, Mantovani HC, Hermsdorff HH, Martino HSD (2019) Synbiotic meal decreases uremic toxins in hemodialysis individuals: a placebo-controlled trial. Food Res Int 116:241–248. https://doi.org/10.1016/j.foodres.2018.08.024CrossRefPubMed

50.

Fontecha-Barriuso M, Martin-Sanchez D, Martinez-Moreno JM, Monsalve M, Ramos AM, Sanchez-Nino MD, Ruiz-Ortega M, Ortiz A, Sanz AB (2020) The role of PGC-1alpha and mitochondrial biogenesis in kidney diseases. Biomolecules 10(2):347. https://doi.org/10.3390/biom10020347

51.

Hong Q, Zhang L, Das B, Li Z, Liu B, Cai G, Chen X, Chuang PY, He JC, Lee K (2018) Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury. Kidney Int 93(6):1330–1343. https://doi.org/10.1016/j.kint.2017.12.008CrossRefPubMedPubMedCentral

52.

Zhang T, Chi Y, Kang Y, Lu H, Niu H, Liu W, Li Y (2019) Resveratrol ameliorates podocyte damage in diabetic mice via SIRT1/PGC-1α mediated attenuation of mitochondrial oxidative stress. J Cell Physiol 234(4):5033–5043. https://doi.org/10.1002/jcp.27306CrossRefPubMed

53.

Kim MY, Lim JH, Youn HH, Hong YA, Yang KS, Park HS, Chung S, Ko SH, Shin SJ, Choi BS, Kim HW, Kim YS, Lee JH, Chang YS, Park CW (2013) Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1alpha axis in db/db mice. Diabetologia 56(1):204–217. https://doi.org/10.1007/s00125-012-2747-2CrossRefPubMed

54.

Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, Park AS, Tao J, Sharma K, Pullman J, Bottinger EP, Goldberg IJ, Susztak K (2015) Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 21(1):37–46. https://doi.org/10.1038/nm.3762CrossRefPubMed

55.

Han SH, Wu MY, Nam BY, Park JT, Yoo TH, Kang SW, Park J, Chinga F, Li SY, Susztak K (2017) PGC-1alpha protects from notch-induced kidney fibrosis development. J Am Soc Nephrol 28(11):3312–3322. https://doi.org/10.1681/ASN.2017020130CrossRefPubMedPubMedCentral

56.

Nam BY, Jhee JH, Park J, Kim S, Kim G, Park JT, Yoo TH, Kang SW, Yu JW, Han SH (2022) PGC-1alpha inhibits the NLRP3 inflammasome via preserving mitochondrial viability to protect kidney fibrosis. Cell Death Dis 13(1):31. https://doi.org/10.1038/s41419-021-04480-3CrossRefPubMedPubMedCentral

57.

Chung KW, Lee EK, Lee MK, Oh GT, Yu BP, Chung HY (2018) Impairment of PPARalpha and the fatty acid oxidation pathway aggravates renal fibrosis during aging. J Am Soc Nephrol 29(4):1223–1237. https://doi.org/10.1681/ASN.2017070802CrossRefPubMedPubMedCentral

58.

Brooks C, Cho SG, Wang CY, Yang T, Dong Z (2011) Fragmented mitochondria are sensitized to Bax insertion and activation during apoptosis. Am J Physiol Cell Physiol 300(3):C447-455. https://doi.org/10.1152/ajpcell.00402.2010CrossRefPubMed

59.

Zhan M, Usman IM, Sun L, Kanwar YS (2015) Disruption of renal tubular mitochondrial quality control by Myo-inositol oxygenase in diabetic kidney disease. J Am Soc Nephrol 26(6):1304–1321. https://doi.org/10.1681/asn.2014050457CrossRefPubMed

60.

Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND (2014) Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 39(3):230–237. https://doi.org/10.1159/000360010CrossRefPubMed

61.

Wang JJ, Zhang QM, Ni WW, Zhang X, Li Y, Li AL, Du P, Li C, Yu SS (2019) Modulatory effect of Lactobacillus acidophilus KLDS 1.0738 on intestinal short-chain fatty acids metabolism and GPR41/43 expression in beta-lactoglobulin-sensitized mice. Microbiol Immunol 63(8):303–315. https://doi.org/10.1111/1348-0421.12723

62.

Li Z, Wang W, Liu D, Guo Y (2017) Effects of Lactobacillus acidophilus on gut microbiota composition in broilers challenged with Clostridium perfringens. PLoS ONE 12(11):e0188634. https://doi.org/10.1371/journal.pone.0188634CrossRefPubMedPubMedCentral

63.

Sivieri K, Morales ML, Adorno MA, Sakamoto IK, Saad SM, Rossi EA (2013) Lactobacillus acidophilus CRL 1014 improved “gut health” in the SHIME reactor. BMC Gastroenterol 13:100. https://doi.org/10.1186/1471-230X-13-100CrossRefPubMedPubMedCentral

64.

Berni Canani R, Sangwan N, Stefka AT, Nocerino R, Paparo L, Aitoro R, Calignano A, Khan AA, Gilbert JA, Nagler CR (2016) Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants. ISME J 10(3):742–750. https://doi.org/10.1038/ismej.2015.151CrossRefPubMed

65.

Duncan SH, Louis P, Flint HJ (2004) Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl Environ Microbiol 70(10):5810–5817. https://doi.org/10.1128/AEM.70.10.5810-5817.2004CrossRefPubMedPubMedCentral

66.

Bourriaud C, Robins RJ, Martin L, Kozlowski F, Tenailleau E, Cherbut C, Michel C (2005) Lactate is mainly fermented to butyrate by human intestinal microfloras but inter-individual variation is evident. J Appl Microbiol 99(1):201–212. https://doi.org/10.1111/j.1365-2672.2005.02605.xCrossRefPubMed

67.

Wang MX, Lin L, Chen YD, Zhong YP, Lin YX, Li P, Tian X, Han B, Xie ZY, Liao QF (2020) Evodiamine has therapeutic efficacy in ulcerative colitis by increasing Lactobacillus acidophilus levels and acetate production. Pharmacol Res 159:104978. https://doi.org/10.1016/j.phrs.2020.104978CrossRefPubMed

68.

Duncan SH, Barcenilla A, Stewart CS, Pryde SE, Flint HJ (2002) Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine. Appl Environ Microbiol 68(10):5186–5190. https://doi.org/10.1128/AEM.68.10.5186-5190.2002CrossRefPubMedPubMedCentral

69.

Kumar A, Alrefai WA, Borthakur A, Dudeja PK (2015) Lactobacillus acidophilus counteracts enteropathogenic E. coli-induced inhibition of butyrate uptake in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 309(7):G602–607. https://doi.org/10.1152/ajpgi.00186.2015

70.

Zhao T, Gu J, Zhang H, Wang Z, Zhang W, Zhao Y, Zheng Y, Zhang W, Zhou H, Zhang G, Sun Q, Zhou E, Liu Z, Xu Y (2020) Sodium butyrate-modulated mitochondrial function in high-insulin induced HepG2 cell dysfunction. Oxid Med Cell Longev 2020:1904609. https://doi.org/10.1155/2020/1904609CrossRefPubMedPubMedCentral

71.

Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F (2016) From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165(6):1332–1345. https://doi.org/10.1016/j.cell.2016.05.041CrossRefPubMed

72.

Lopez-Armada MJ, Riveiro-Naveira RR, Vaamonde-Garcia C, Valcarcel-Ares MN (2013) Mitochondrial dysfunction and the inflammatory response. Mitochondrion 13(2):106–118. https://doi.org/10.1016/j.mito.2013.01.003CrossRefPubMed

73.

Yu JW, Lee MS (2016) Mitochondria and the NLRP3 inflammasome: physiological and pathological relevance. Arch Pharm Res 39(11):1503–1518. https://doi.org/10.1007/s12272-016-0827-4CrossRefPubMed

Title: Lactobacillus acidophilus KBL409 protects against kidney injury via improving mitochondrial function with chronic kidney disease
Authors: Jimin Park
Ki Heon Nam
Bo Young Nam
Gyuri Kim
Hyoungnae Kim
Ki Uk Lee
Seok Cheon Song
Tae-Wook Nam
Woon-Ki Kim
Jung Tak Park
Tae-Hyun Yoo
Shin-Wook Kang
GwangPyo Ko
Seung Hyeok Han
Publication date: 06-05-2024
Publisher: Springer Berlin Heidelberg
Keywords: Chronic Kidney Disease
Probiotics
Kidney Injury
Published in: European Journal of Nutrition
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-024-03408-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com